Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer

Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis that is driven primarily by oncogenic KRAS mutations present in > 90% of cases. KRAS mutations, particularly the G12D mutation which dominates in PDAC, fuel tumor initiation, progression, and immune evasion,...

Full description

Saved in:
Bibliographic Details
Main Authors: Nawaz Khan, Umar Raza, Syed Aqib Ali Zaidi, Muhadaisi Nuer, Kayisaier Abudurousuli, Yipaerguli Paerhati, Alifeiye Aikebaier, Wenting Zhou
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-07-01
Series:Cancer Biology & Medicine
Subjects:
pancreatic cancer
kras mutations
kras inhibitors
therapy resistance
immunotherapy
Online Access:https://www.cancerbiomed.org/content/22/7/762
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.cancerbiomed.org/content/22/7/762

Similar Items